Congress is considering a bill that could deter billions of dollars of medical research investments, undermining U.S. global leadership as a healthcare innovator and harming U.S. patients. That’s not Congress’s intent, of course. https://t.co/1mWXWXLdLC
What was meant to be a patient-focused program is now a hospital markup program where large, tax-exempt hospital systems buy discounted drugs, mark them up by as much as 1,000% or more and bill patients and insurers the list price. https://t.co/5NpiCibXJi
Here’s a paradox for you to think over: half of all new medicines are developed in the United States, yet Americans pay two to three times more for those medicines than people in other developed countries.
If it sounds unfair, that’s because it is. https://t.co/s8NWdUS7E5
Since the end of WWII, we've spent trillions of dollars defending Europe. After defeating the Nazis, America rebuilt the European continent with the Marshall Plan & shielded it from Soviet aggression while propping up economies via subsidies & investments. https://t.co/9YuWONGnKD
For thousands of families, Easterseals of Central & Southeast OH provides programs that deliver equality, dignity & independence to those with disabilities. Success is achieving a world where each child, adult & older person is 100% included & empowered. https://t.co/JdiczcMOkA
“Most-favored-nation” pricing risks sending America’s leadership in innovation down the same slope that has diminished Europe’s biopharmaceutical capacity and capabilities. https://t.co/TMS9oogaDP
Small business owners are struggling to keep up with the rising cost of healthcare. Nearly a third have recently stopped offering health benefits as premiums continue to climb. https://t.co/I58uL0ktvx
The next breakthrough therapy may still be marketed in New York or Basel. But increasingly, it is being born in Shanghai. China’s pharmaceutical industry has moved beyond imitation into something more consequential: early-stage innovation at scale. https://t.co/06up2RirKK
Gene therapy breakthroughs, the first oral GLP-1, a troubling signal for scientific talent & a German pricing move that could reshape global drug development. John Stanford breaks down 4 stories shaping the future of life sciences & biotech investment. https://t.co/t7BbEFr0fk
What does a new healthcare reform effort in Germany have to do with U.S. patients? A lot actually. Their gov. is looking to cut healthcare spending by tens of billions. To that end, it's pushing pharmaceutical companies to accept lower prices for new meds. https://t.co/H6gkSg83c4
For months, the Trump admin. has floated the idea of a formal investigation into foreign countries' unfair drug pricing practices -- an implicit threat intended to push our allies into proactively reforming those practices, without need for overt pressure. https://t.co/dguXTFQtGk
The latest push in D.C. to lower healthcare costs is overlooking the needs of those with the most at stake: Latino patients. Carrying some of the highest rates of chronic disease in the country, latino adults are more likely to develop diabetes. https://t.co/qOn4ongGkC
Pres. Trump announced an agreement with Regeneron Pharmaceuticals to apply MFN pricing to future meds for U.S. patients. Despite the spin about how this will lower drug prices, it actually imports foreign price controls that undermine medical innovation. https://t.co/xWP1P9p8qk
In times of uncertainty, the pressure to “do something” is real. But too often, that instinct leads policymakers to turn to government intervention that risks undermining the very system that has driven American prosperity. https://t.co/8aO7AZ2OrF
Pres. Trump’s work to lower prescription med. costs for patients will be one of his most notable legacies. From the legislation he recently signed to the historic pricing deals he's negotiated, he's made more progress on this than his modern predecessors. https://t.co/mmP6aPY39h
For generations, rural hospitals have been more than just places to receive medical care. They are community lifelines that provide jobs and make the difference between life and death when emergencies strike miles from the nearest city. https://t.co/JaZQvBLAge
Incubate, in partnership with Manatt Health, released new insights from interviews with leading biopharmaceutical investors showing that instability at the Food and Drug Administration (FDA) is increasingly shaping investment decisions. https://t.co/IJOd2VHFS7
When policymakers discuss “drug price controls,” it’s often framed as a commonsense solution to rising costs. I understand that impulse. As a former PA legislator & breast cancer survivor, I know firsthand how stressful & expensive serious illness can be. https://t.co/RoNkPgaePl
Medical breakthroughs are often measured in lives saved & diseases prevented. That's only part of the story--they're also a strong driver of economic growth, workforce strength & long-term public revenue. In Frederick Co., the connection isn't theoretical. https://t.co/eE9UBRZ148
North Carolina's economic success didn't happen by accident. It's the result of decades of policies designed to encourage investment, reward innovation, and allow markets to work. Read more: https://t.co/8ou9ALMth8